Sagitta Biotech

📍 Liège, Belgium🗓 Founded 2019👥 3 employees💰 Last funded Dec 2023
Biotechnology🌐 sagittabiotech.com
Website LinkedIn
Sagitta Biotech is a company developping an innovative viral vector to develop efficient vaccines, oncolytic viruses and gene therapy vectors. Our active virosome platform can deliver up to 17kb mRNA (6 genes), and elicit both humoral and cellular reponse. Sagitta is developping its own pipeline of innovative multivalent vaccines (currently in preclinical phases) and oncolytic viruses, and is open to partnering and co-development. In ancient Greece, Sagitta was regarded as the weapon that Hercules used to kill the eagle (Aquila) of Jove that perpetually gnawed Prometheus​ liver.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Belgium
1
Frequently asked questions
Who invested in Sagitta Biotech?
Sagitta Biotech has 1 investors on record on gritt.io, 1 mid-stage.
When did Sagitta Biotech last raise funding?
The most recent investment in Sagitta Biotech recorded on gritt.io was in December 2023.
When was Sagitta Biotech founded?
Sagitta Biotech was founded in 2019.
What industry is Sagitta Biotech in?
Sagitta Biotech operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Sagitta Biotech based?
Sagitta Biotech is headquartered in Liège, Belgium.